• Eyes that are naive to treatment with pegcetacoplan that are prescribed pegcetacoplan per routine clinical practice according to approved pegcetacoplan prescribing information (ie, the clinical decision to treat with pegcetacoplan must be made before study participation is discussed with the patient)

• Patient age ≥60 years

• Visual acuity better than 20/200 on Snellen chart

• Clinical diagnosis of GA of the macula secondary to AMD in one or both eyes as determined by the investigator using OCT and/or FAF imaging

• GA lesion meeting the following criteria as determined by the investigator's assessment of Spectralis OCT and/or FAF images at screening:

‣ Nonsubfoveal lesion(s)

⁃ GA lesion visualized in its entirety on the macula-centered OCT image and not contiguous with any areas of peripapillary atrophy

⁃ Presence of any pattern of hyperautofluorescence in the junctional zone of GA; absence of hyperautofluorescence (ie, pattern = none) exclusionary

• Adequate clarity of ocular media and adequate pupillary dilation and fixation to permit the collection of good quality images as determined by the investigator

• Patient willing and able to give informed consent and to comply with the study procedures and assessments